Zydus Lifesciences Ltd - 532321 - Investor Conference
The Company will be participating in Axis Capital India Conference 2023 at Mumbai on February 7, 202306-02-2023
06-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication04-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Link of Audio Recording of Investor Call03-02-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201503-02-2023
Q3FY23 Quarterly Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals firm Zydus Lifesciences announced Q3FY23 results: Q3FY23: Revenue from operations at Rs 43,623 million, up 20% over last year. Research & development (R&D;) investments for the quarter stood at Rs 3,435 million (7.9% of revenues). EBITDA for the quarter was Rs 9,560 million, up 27% YoY. EBITDA margin for the quarter was 21.9% against 20.6% in Q3FY22. Net profit for the quarter was Rs 6,229 million, up 24% YoY. Capex (organic) for the quarter was Rs 2,554 million. 9MFY23: Revenue from operations at Rs 1,25,697 million, up 10% over last year. Adjusting for COVID-related revenues in last year’s base, growth was 16% YoY. Research & development (R&D;) investments for nine months stood at Rs 8,811 million (7% of revenues). EBITDA for nine months was Rs 26,043 million, down 1% YoY. EBITDA margin for the period stood at 20.7% against 23% last year. Adjusted for COVID-related inventory provision, the EBITDA margin for nine months was 21.7% of revenues. Net profit for nine months was Rs 16,637 million. Adjusted for inventory provision, exceptional items and profit/ (loss) from discontinued operations, net profit for the nine months was down 1% YoY. Capex (organic) for the nine months was Rs 7,539 million Dr. Sharvil Patel, Managing Director - of Zydus Lifesciences Limited, said: "We are pleased with our Q3FY23 performance showcasing robust growth across key businesses and improved profitability. With India Formulations in a double-digit growth trajectory and US business continuing to build traction, portfolio execution will sustain growth momentum. We aim to enhance profitability steadily going ahead while remaining committed to build long term growth levers. Our commitment to maintaining high quality standards and an agile supply chain positions us well to capitalize on our R&D; pipeline and advance our innovation efforts." Result PDF03-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached the Investor Presentation on the unaudited financial results for the quarter / nine months ended on December 31, 2022.03-02-2023
Zydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2022
The Board of Directors at their meeting held today i.e. February 3, 2023, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / nine months ended on December 31, 2022.03-02-2023
Zydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2022
The Board of Directors at their meeting held today i.e. February 3, 2023, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / nine months ended on December 31, 2022.03-02-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q3 FY23 post results earning call details30-01-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We wish to inform that the USFDA conducted an inspection at the manufacturing facility of Zydus Lifesciences Limited located at Moraiya, Ahmedabad from 23rd to 27th January, 2023. The inspection was a Pre-Approval Inspection (PAI) for Transdermal Patch products. The inspection concluded with NIL observations.27-01-2023